Citius Oncology (CTOR) Net Cash Flow (2023 - 2026)

Citius Oncology (CTOR) has reported Net Cash Flow for 4 consecutive years, with $13.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow changed N/A year-over-year to $13.9 million in Q2 2026; TTM through Jun 2026 was $12.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $3.9 million, up 3504182.14% from the prior year.
• Net Cash Flow was $13.9 million for Q2 2026 at Citius Oncology, up from -$4.7 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $13.9 million in Q2 2026 and troughed at -$4.7 million in Q1 2026.
• A 4-year average of $1.5 million and a median of -$66662.5 in 2023 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 100.35% in 2024, down 67.02% in 2024.
• Over 4 years, Net Cash Flow stood at -$262652.0 in 2023, then soared by 87.41% to -$33069.0 in 2024, then jumped by 10292.46% to $3.4 million in 2025, then surged by 313.32% to $13.9 million in 2026.
• The last three Net Cash Flow figures came in at $13.9 million (Q2 2026), -$4.7 million (Q1 2026), and $3.4 million (Q4 2025), per Business Quant data.